ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease

Wang, Dan; Zhang, Zikun; Si, Zekun; Yang, Yanlin; Li, Shuangshuang; Xue, Yaoming*南方医科大学
FEBS Open Bio2021-5DOI: 10.1002/2211-5463.13147
14被引14阅读
引用收藏
分享

摘要

An imbalance between T helper 17 (Th17) and T regulatory (Treg) cell subsets contributes to the pathogenesis of diabetic kidney disease (DKD). However, the underlying regulatory mechanisms that cause this imbalance are unknown. Serum/glucocorticoid-regulated kinase 1 (SGK1) has been suggested to affect Th17 polarization in a salt-dependent manner, and sodium/glucose cotransporter 2 inhibitors (SGLT2i) have been demonstrated to regulate sodium-mediated transportation in the renal tubules. This study aimed to evaluate the potential benefits of dapagliflozin (Dap) on DKD, as well as its influence on shifting renal T-cell polarization and related cytokine secretion. We treated male db/db mice with Dap or voglibose (Vog) and measured blood and kidney levels of Th17 and Treg cells using flow cytometry. We found that Th17 cells were significantly increased, while Treg cells were significantly decreased in diabetic mice. Moreover, Dap suppressed the polarization of Th17/Treg cells by inhibiting SGK1 in diabetic kidneys, and this was accompanied by attenuation of albuminuria and tubulointerstitial fibrosis independent of glycemic control. Taken together, these results demonstrate that the imbalance of Th17/Treg cells plays an important role in the progression of DKD. Moreover, Dap protects against DKD by inhibiting SGK1 and reversing the T-cell imbalance.

学科与关键词

关键词
diabetic kidney diseaseinflammatory responseserumglucocorticoid&#8208regulated kinase 1sodiumglucose co&#8208transporter 2Th17Treg cell imbalance
相关
加载中…
  • Dapagliflozin attenuates renal fibrosis by suppressing angiotensin II/TGFβ signaling in diabetic mice
    Jiang, Mingwang; Yang, Zhichen; Lyu, Lu*; Shi, Meng*JOURNAL OF DIABETES AND ITS COMPLICATIONS, 2024, 38(2): 108687.
  • Dapagliflozin alleviates advanced glycation end product induced podocyte injury through AMPK/mTOR mediated autophagy pathway
    Yang, Lei; Liang, Baozhu; Li, Jingxin; Zhang, Xiaoyan; Chen, Hong; Sun, Jia; Zhang, Zhen*Cellular Signalling, 2022, 90: 110206.被引 22
  • IL-17A in diabetic kidney disease: protection or damage
    Tan, Hai-Bo*; Zheng, Yan-Qiu; Zhuang, Yu-PeiInternational Immunopharmacology, 2022, 108: 108707.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
FEBS Open Bio
发表日期
2021-05
卷期
第 11 卷, 第 5 期
页码
1395-1405
DOI
10.1002/2211-5463.13147
语言
ENGLISH
期刊收录
NSL
期刊等级
4区
成果收录
SCIE
资助标注
Dean Foundation of Nanfang Hospital [2016C025]; National Natural Science Foundation of China [81900759]

作者

  • W

    Wang, Dan (第一作者)

    southern med univ

  • Z

    Zhang, Zikun

    southern med univ

查看全部 6 位作者收起作者
  • S

    Si, Zekun

    southern med univ

  • Y

    Yang, Yanlin

    southern med univ

  • L

    Li, Shuangshuang

    southern med univ

  • X

    Xue, Yaoming (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417